Related Experiment Videos
Short course chemotherapy for tuberculosis in children
R Padmini1, S Srinivasan, P Nalini
1Department of Pediatrics, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, India.
Journal of Tropical Pediatrics
|December 1, 1993
Summary
Short course chemotherapy (SCC) for childhood tuberculosis is highly effective. This 6-9 month treatment regimen using isoniazid and rifampicin showed excellent results with minimal side effects in children.
Area of Science:
- Pediatrics
- Infectious Diseases
- Pharmacology
Background:
- Tuberculosis (TB) remains a significant global health challenge in children.
- Conventional chemotherapy for pediatric TB often requires prolonged treatment durations (18+ months).
- The need for shorter, effective treatment regimens is critical for improving adherence and outcomes.
Purpose of the Study:
- To evaluate the efficacy and safety of short course chemotherapy (SCC) for treating tuberculosis in children under 12 years old.
- To compare SCC outcomes with conventional, longer-duration chemotherapy.
- To assess the tolerability and side effects of SCC in pediatric patients.
Main Methods:
- A prospective study involving 83 newly diagnosed pediatric TB cases (< 12 years old).
- Patients received SCC, with treatment durations of 6-9 months for mild/moderate cases and 12 months for severe cases (meningitis, disseminated, miliary TB).
- Follow-up ranged from 1-3 years to monitor for disease recurrence and adverse events.
Main Results:
- No children exhibited evidence of active tuberculosis at the end of the follow-up period.
- The SCC regimen was well-tolerated, with only mild, transient side effects reported (hepatitis, vomiting, skin rash).
- SCC demonstrated high efficacy, with 100% of patients achieving a cure.
Conclusions:
- Short course chemotherapy (SCC) for 6-9 months, primarily using isoniazid and rifampicin, is highly effective for most pediatric tuberculosis cases.
- SCC offers significant advantages over conventional chemotherapy, including shorter duration and good tolerability.
- This treatment approach presents a promising alternative for managing childhood tuberculosis, potentially improving patient compliance and outcomes.